Tag:
vipadenant
Latest Headlines
Latest Headlines
Vernalis Parkinson's drug sinks on tox issues
Vernalis and partner Biogen Idec have halted development of the drug vipadenant (V2006/BIIB014), an A2A receptor antagonist program in development for the treatment of Parkinson's. Though the drug
